Healthcare / Medical Instruments & SuppliesTSXV
$2.21
+0.04 (+1.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $1.4M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$61M
P/E
44.2x
↑EV/EBITDA
17.1x
↑ROE
6.7%
↑Gross Margin
53.2%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.8%
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.8M · net income $2.1M · FCF $1.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.8M | $32.8M | $31.2M | $26.6M | $18.1M |
| Net Income | $2.1M | $2.1M | $2.7M | $-4.5M | $-9.7M |
| EBITDA | $2.7M | $2.7M | $3.1M | $-3.6M | $-8.1M |
| EPS | 0.07 | 0.07 | 0.11 | -0.18 | -0.36 |
| Gross Margin | 53.2% | 53.2% | 60.7% | 54.0% | 41.3% |
| Operating Margin | 5.4% | 5.4% | 6.9% | -17.0% | -50.4% |
| Net Margin | 6.3% | 6.3% | 8.6% | -16.8% | -53.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.03 | 0.08 | 0.09 |
| Current Ratio | 7.57 | 7.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.4M | $1.4M | $3.1M | $-4.5M | $-9.1M |
| Returns | |||||
| ROE | 6.7% | 6.7% | 9.7% | -23.7% | -39.9% |
| Valuation | |||||
| P/E | 44.20 | 44.20 | 29.27 | — | — |
| EV/EBITDA | 17.12 | 17.12 | 19.86 | — | — |
| P/B | 2.01 | 2.01 | 2.84 | 1.91 | 2.45 |
| Growth & Yield | |||||
| Revenue Growth | 5.3% | 5.3% | 17.2% | 46.6% | — |
| EPS Growth | -36.4% | -36.4% | 161.1% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.0%
EPS terminal req.
$0.20
Spread vs growth
-77.3%
5Y implied EPS CAGR
27.7%
EPS terminal req.
$0.24
Spread vs growth
-64.0%
10Y implied EPS CAGR
18.5%
EPS terminal req.
$0.38
Spread vs growth
-54.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.4%
Start / end P/E
22.2x → 31.6x
EPS bridge
0.11 → 0.07
Residual
-15.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.